Backgrounds An increasing incidence of Acute Myeloid Leukaemia (AML) has been
reported in several Western countries. However, the epidemiology of AML in Asia is very …

Background Comorbidities in acute myeloid leukemia (AML) patients have been shown to
increase with age. However, few studies have described the disease burden in elderly AML …

Simple Summary The history of the treatment of APL has shown remarkable success.
However, it is not clear whether it is necessary to monitor long-term toxicity in “cured” …

Selinexor, a selective inhibitor of nuclear export, has demonstrated promising activity in
patients with acute myeloid leukemia (AML). This randomized, phase II study evaluated …

Genetic and morphological markers are well-established prognostic factors in acute myeloid
leukemia (AML). However, further reliable markers are urgently needed to improve risk …

The association between serum albumin level and clinical outcomes has been reported for
several hematological malignancies. Our study aimed to identify the relationship between …

Despite improvements in our understanding of the molecular basis of acute myeloid
leukemia (AML), the association between genetic mutations with morphological dysplasia …

In epigenetic mechanisms, DNA methyltransferase 3 alpha (DNMT3A) acts as an initiator for
DNA methylation and prevents the downstream genes from expressing. Perturbations of …

Treatment response assessment in multiple myeloma (MM) relies on the detection of
paraprotein in serum and/or urine, bone marrow morphology and immunohistochemistry …

Background: Acute myeloid leukemia (AML) is a disease of the hematopoietic system that
remains a therapeutic challenge despite advances in our understanding of the underlying …